Soluble Production of Human Recombinant VEGF-A121 by Using SUMO Fusion Technology in Escherichia coli
Human recombinant vascular endothelial growth factor-A121 (hrVEGF-A121) has applications in pharmaceutical industry especially in regenerative medicine. Here, we report the expression, purification, and characterization of hrVEGF-A121 in Escherichia coli expression system using human small ubiquitin-related modifier-3 (hSUMO3) fusion partner. Total RNA was isolated from healthy human gingival tissue, VEGF-A121 gene was RT-PCR amplified, and hSUMO3 gene was tagged at N-terminus. The fusion gene (SUMO3-VEGF-A121) was cloned in pET-22b(+) expression vector and transferred into E. coli strains; BL21 codon + and Rosetta-gami B(DE3). The hrVEGF-A121 expression was optimized for temperature, IPTG concentration, and time in Terrific Broth (TB). The positive transformants were sequenced and hrVEGF-A121 nucleotide sequence was submitted to Genbank (Accession No. KT581010). Approximately 40% of total cell protein expression was observed in soluble form on 15% SDS-PAGE. The hSUMO3 was cleaved from hrVEGF-A121 with SUMO protease and purified by Fast Protein Liquid Chromatography using anionic Hi-trap Resource Q column. From 100 ml TB, ~ 25.5% and ~ 6.8 mg of hrVEGF-A121 protein was recovered. The dimerized hrVEGF-A121 was characterized by Native PAGE and Western blot, using human anti-VEGF-A antibody and ESI-MS showed dimeric hrVEGF-A121 at 31,015 Da. The biological activity of hrVEGF-A121 was assessed in vitro by MTT and cell viability assay and observed to be bioactive.
KeywordsHrVEGF-A121 hSUMO3 Rosetta-gami B (DE3) Fast protein liquid chromatography ESI-MS MTT
All the authors have seen and approved the manuscript and performed their responsibilities in designing the project, experimental work, and manuscript write up.
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no financial or commercial conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 2.Yazdanfar, M., Bandehpour, M., Yarian, F., Koochaki, A., Parivar, K., & Kazemi, B. (2010). Cloning and expression of human vascular endothelial growth factor gene and inhibition of its expression by antisense in prokaryotic system. Daru, 18(4), 281–285.Google Scholar
- 4.Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., Declercq, C., Pawling, J., Moons, L., Collen, D., Risau, W., & Nagy, A. (1996). Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature, 380(6573), 435–439.CrossRefGoogle Scholar
- 10.Taktak-BenAmar, A., Morjen, M., Mabrouk, B., Abdelmaksoud-Dammak, H., Guerfali, R., Fourati-Masmoudi, M., Marrakchi, N., and Gargouri, A. (2017). Expression, purification and functionality of bioactive recombinant human vascular endothelial growth factor VEGF165 in E. coli. AMB Express, 7(1), 33.CrossRefGoogle Scholar
- 14.Lee, S. B., Park, J. S., Lee, S., Park, J., Yu, S., Kim, H., Kim, D., Byun, T. H., Baek, K., Ahn, Y. J., & Yoon, J. (2008). Overproduction of recombinant human VEGF (vascular endothelial growth factor) in Chinese hamster ovary cells. Journal of Microbiology and Biotechnology, 18(1), 183–187.Google Scholar
- 15.Hu, Z. M., Ma, L., Zhou, M. Q., Gao, J. M., & Wang, X. N. (2006). Refolding and purification of recombinant human VEGF-121 expressed as inclusion bodies in Escherichia coli. Nan Fang Yi Ke. Da Xue Xue Bao, 26(8), 1083–1086.Google Scholar
- 16.Costa, S., Almeida, A., Castro, A., & Domingues, L. (2014). Fusion tags for protein solubility, purification and immunogenicity in Escherichia coli: The novel Fh8 system. Frontiers in Microbiology, 5, 63.Google Scholar
- 21.Kazemi-Lomedasht, F., Behdani, M., Pooshang Bagheri, K., Habibi Anbouhi, M., Abolhassani, M., Khanahmad, H., Shahbazzadeh, D., & Mirzahoseini, H. (2014). Expression and purification of functional human vascular endothelial growth factor-A121; the most important angiogenesis factor. Advanced Pharmaceutical Bulletin, 4(4), 323–328.Google Scholar
- 22.Shima, D. T., Kuroki, M., Deutsch, U., Ng, Y. S., Adamis, A. P., & D’Amore, P. A. (1996). The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences. Journal of Biological Chemistry, 271(7), 3877–3883.CrossRefGoogle Scholar
- 31.Hanif, M. U., Yaseen, A., Gul, R., Mirza, M. U., Nawaz, M. H., Ahmed, S. S., Aziz, S., Chaudhary, S., Khan, A. A., & Shoaib, M. (2018). Small ubiquitin-like modifier protein 3 enhances the solubilization of human bone morphogenetic protein 2 in E. coli. Applied Biochemistry and Biotechnology. https://doi.org/10.1007/s12010-018-2736-0.Google Scholar
- 36.Das, K. M., Banerjee, S., Shekhar, N., Damodaran, K., Nair, R., Somani, S., Raiker, V. P., Jain, S., & Padmanabhan, S. (2011). Cloning, soluble expression and purification of high yield recombinant hGMCSF in Escherichia coli. International Journal of Molecular Sciences, 12(3), 2064–2076.CrossRefGoogle Scholar
- 41.Yuan, A., Lin, C. Y., Chou, C. H., Shih, C. M., Chen, C. Y., Cheng, H. W., Chen, Y. F., Chen, J. J., Chen, J. H., Yang, P. C., & Chang, C. (2011). Functional and structural characteristics of tumor angiogenesis in lung cancers overexpressing different VEGF isoforms assessed by DCE- and SSCE-MRI. PLoS ONE, 6(1), e16062.CrossRefGoogle Scholar
- 42.Yang, Y., Zhang, S., Howe, K., Wilson, D. B., Moser, F., Irwin, D., & Thannhauser, T. W. (2007). A comparison of nLC-ESI-MS/MS and nLC-MALDI-MS/MS for GeLC-based protein identification and iTRAQ-based shotgun quantitative proteomics. Journal of Biomolecular Techniques, 18(4), 226–237.Google Scholar
- 43.Shi, X., Chen, G., Xing, H., Weng, D., Bai, X., & Ma, D. (2007). VEGF-C, VEGFR-3, and COX-2 enhances growth and metastasis of human cervical carcinoma cell lines in vitro. Oncology Reports, 18(1), 241–247.Google Scholar